• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

COA Applauds CMS' Decision on CAR T-Cell Therapy

Article

Following CMS’ decision to make chimeric antigen receptor (CAR) T-cell therapy available to Medicare beneficiaries nationwide, including in the community oncology setting, the Community Oncology Alliance (COA) applauded the decision.

Following CMS’ decision to make chimeric antigen receptor (CAR) T-cell therapy available to Medicare beneficiaries nationwide, including in the community oncology setting, the Community Oncology Alliance (COA) applauded the decision. According to COA, the agency listened to the feedback of community practices by ensuring that CAR T-cell therapy is covered outside of the hospital setting.

COA is also pleased that by protecting Medicare beneficiaries, the agency has streamlined the reporting requirements and aligned requirements between CMS and the FDA, which will reduce burden for providers, Medicare, and patients.

Read the full press release.

Related Videos
Rakendu Rajendran, MBBS
Vivek Bhalla, MD, Stanford University School of Medicine
Rayan Salih, MD, Northeast Georgia Health System
Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Mount Sinai Fuster Heart Hospital
Varsha Tanguturi, MD, MPH, Mass General Hospital
 Khush Kharidia, MD, UT Southwestern
Alexandra M. Trevino, MD, Northwestern Medicine
Nicole Bajic, MD
Dr Sundar Jagannath
Andrew Kuykendall, MD, Moffitt Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.